about
The Hippo pathway regulates Wnt/beta-catenin signalingTAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewalThe Hippo pathway effectors TAZ and YAP in development, homeostasis and diseaseProtein N-glycosylation in oral cancer: dysregulated cellular networks among DPAGT1, E-cadherin adhesion and canonical Wnt signalingAn allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzymeThe hippo pathway effector Yap controls patterning and differentiation of airway epithelial progenitorsThe transcriptional regulators TAZ and YAP direct transforming growth factor β-induced tumorigenic phenotypes in breast cancer cells.The Hippo pathway effector YAP is an essential regulator of ductal progenitor patterning in the mouse submandibular gland.Notch3-Jagged signaling controls the pool of undifferentiated airway progenitors.Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosisA YAP/TAZ-Regulated Molecular Signature Is Associated with Oral Squamous Cell Carcinoma.Crumbs3-Mediated Polarity Directs Airway Epithelial Cell Fate through the Hippo Pathway Effector Yap.TAZ activation drives fibroblast spheroid growth, expression of profibrotic paracrine signals, and context-dependent ECM gene expression.Altered RNA editing in 3' UTR perturbs microRNA-mediated regulation of oncogenes and tumor-suppressorsN-glycosylation induces the CTHRC1 protein and drives oral cancer cell migration.The Hippo signaling pathway is required for salivary gland development and its dysregulation is associated with Sjogren's syndromeSystematic morphological profiling of human gene and allele function via Cell Painting.Coordinating developmental signaling: novel roles for the Hippo pathway.Stem cell regulation by the Hippo pathway.The Hippo pathway effectors TAZ/YAP regulate dicer expression and microRNA biogenesis through Let-7The ubiquitin binding region of the Smurf HECT domain facilitates polyubiquitylation and binding of ubiquitylated substrates.Phosphorylation of the tumor suppressor fat is regulated by its ligand Dachsous and the kinase discs overgrown.Distinct polarity cues direct Taz/Yap and TGFβ receptor localization to differentially control TGFβ-induced Smad signaling.Switch enhancers interpret TGF-β and Hippo signaling to control cell fate in human embryonic stem cells.Expression of Piwi protein MIWI2 defines a distinct population of multiciliated cells.Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis.Inhibition of LSD1 epigenetically attenuates oral cancer growth and metastasis.Therapeutic Targeting of TAZ and YAP by Dimethyl Fumarate in Systemic Sclerosis Fibrosis.Integrin-FAK-CDC42-PP1A signaling gnaws at YAP/TAZ activity to control incisor stem cells.Arterial stiffness induces remodeling phenotypes in pulmonary artery smooth muscle cells via YAP/TAZ-mediated repression of cyclooxygenase-2.The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-β-SMAD pathway.Purification and properties of the ubiquitin-conjugating enzymes Cdc34 and Ubc13.Mms2.Hsp70-Bag3 complex is a hub for proteotoxicity-induced signaling that controls protein aggregationFunctional and genomic analyses reveal therapeutic potential of targeting β-catenin/CBP activity in head and neck cancerGlutamine-utilizing transaminases are a metabolic vulnerability of TAZ/YAP-activated cancer cellsHead and neck cancer: from research to therapy and curePhosphatidic Acid Signals via the Hippo PathwayCaDrA: A Computational Framework for Performing Candidate Driver Analyses Using Genomic FeaturesThe in vivo genetic program of murine primordial lung epithelial progenitorsTGFβ-induced fibroblast activation requires persistent and targeted HDAC-mediated gene repression
P50
Q24307606-73C43E0B-8202-48C9-912A-B4CD85E9EC7DQ24323998-CD60CC91-B556-472D-AF14-ABBE9B8B4DFBQ26852353-405E90BF-193B-4E61-BD6B-A67CB2FFA293Q26861795-540FE6EA-35CA-4A4B-9CEA-1C7732D9CBA1Q27670465-95BFF396-3BB5-4002-AB29-2F8A3E9645F9Q28506288-299F9626-C160-402E-8569-56C6E05AA88EQ33676720-45BF97C5-66CC-4EFF-BBDA-825F3CEE8E38Q33784111-ACFD10EC-C2F9-4CAA-817A-EF23430B1FAEQ34999132-F2E22DC8-99FF-4C38-9C97-F3C76C916DDDQ35086389-330B4CC4-A6B0-4021-B65E-27D21A17EE7AQ35752244-2839BFA9-D78E-449B-A0AD-EC87D9B9A494Q35952181-EE29A3A2-8984-4335-806A-D199165E5122Q36203073-4A0494B1-2564-4E55-8EED-97E13F8FA4C7Q36690990-619D0A76-6E04-43C7-B934-CA7B45604FF6Q37012394-91CD577C-69F0-421C-9B89-A4B4FCE19635Q37396388-C53ED362-4B7B-436C-800B-720780B7261EQ37745645-06C8AD19-D5CB-4798-B014-10EB4BFCEED4Q37966260-D66A0FA5-F867-4CA7-8BD5-6F029F8AE466Q38028698-3596A211-799B-4493-9F9D-4D88BF04A21CQ39044895-08DFADAE-375E-4EFE-A279-83695F21AD2FQ39760437-B01348BB-8CC8-4875-8A11-CE5EC6793B14Q39835885-DFB21CFD-D29C-45E9-A41E-5C10BCED2895Q42473991-D8327BEB-B379-4FD4-B009-AE674534AA3DQ45919103-F6077396-A46D-4854-B834-F6F1414F0F6DQ47106856-EFA0C356-3E22-40FC-B4F1-9B47A76EBBAAQ47252515-33DB7B00-B377-4208-89CB-56D6AE8C983AQ47582238-ED29F41E-77F6-4221-9D15-52F47219F65EQ47718418-E5496BE2-5225-40CF-8B99-2CB114CFC5B3Q47772615-944CC643-4B78-46FB-A725-FF1329054219Q47993375-3E5264DC-F283-4DE2-AC11-00167DF663C2Q52605847-151BBF19-6370-4E3C-A446-5023B30634B0Q54475545-22572079-DA0E-4E4B-8BBD-A66C15D53889Q58197288-32EC32C7-3285-4843-AF20-3B92128A533FQ58197289-4CFC40C0-084E-4ED3-80F9-4338E6DC6E37Q58197290-73A9E8FE-73A7-420C-B3D2-69D1F1FB8249Q58197295-28163AB8-48A1-4C92-82C4-A671CC61755BQ58599898-74A2D1EF-1165-4230-88F8-D484479C70E5Q64229386-279B6BB1-C583-45FF-B954-D6CD0CCA0400Q89474518-1615F7CF-8D80-4201-8F6C-324436AF1622Q90131166-C7A42DE6-B556-47E3-9142-04AE19D69D86
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Xaralabos Varelas
@ast
Xaralabos Varelas
@en
Xaralabos Varelas
@es
Xaralabos Varelas
@nl
Xaralabos Varelas
@sl
type
label
Xaralabos Varelas
@ast
Xaralabos Varelas
@en
Xaralabos Varelas
@es
Xaralabos Varelas
@nl
Xaralabos Varelas
@sl
altLabel
Bob Varelas
@en
prefLabel
Xaralabos Varelas
@ast
Xaralabos Varelas
@en
Xaralabos Varelas
@es
Xaralabos Varelas
@nl
Xaralabos Varelas
@sl
P106
P21
P31
P496
0000-0002-2882-4541